DIVI S LABORATORIES LTD vs METROPOLIS HEALTHCARE LTD

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and METROPOLIS HEALTHCARE LTD (METROPOLIS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs METROPOLIS on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

74.93
P/E ratio
59.47
10.72
P/B ratio
7.46
0.44%
Dividend yield
0.89%
₹96.73
EPS
₹9.17

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
13.80%
22.00%
Return on capital
18.00%
33.00%
EBITDA margin
24.00%
24.32%
Net margin
11.60%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
12.76%
12.10%
Profit CAGR (3Y)
10.13%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.92L Cr
Market cap
₹11,323 Cr
₹10,560 Cr
Revenue
₹1,646 Cr
₹2,568 Cr
Net profit
₹191 Cr
0.00
Debt / equity
0.15
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 10.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
METROPOLIS HEALTHCARE LTD
  • ["Stock is trading at 7.78 times its book value", "The company has delivered a poor sales growth of 10.5% over past five years.", "Company has a low return on equity of 12.6% over last 3 years."]
DIVI S LABORATORIES LTD full analysis METROPOLIS HEALTHCARE LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

DIVI S LABORATORIES LTD vs METROPOLIS HEALTHCARE LTD: Share Price, Valuation & Which to Buy | DocStoX